Volume 346, Issue 6 pp. 447-454
Full Paper

Synthesis and Biological Evaluation of Novel Bromophenol Derivatives as Carbonic Anhydrase Inhibitors

Yusuf Akbaba

Yusuf Akbaba

Faculty of Science, Department of Chemistry, Atatürk University, Erzurum, Turkey

Search for more papers by this author
Halis Türker Balaydın

Halis Türker Balaydın

Faculty of Education, Science Educating Department, Artvin Coruh University, Artvin, Turkey

Search for more papers by this author
Abdullah Menzek

Abdullah Menzek

Faculty of Science, Department of Chemistry, Atatürk University, Erzurum, Turkey

Search for more papers by this author
Süleyman Göksu

Süleyman Göksu

Faculty of Science, Department of Chemistry, Atatürk University, Erzurum, Turkey

Search for more papers by this author
Ertan Şahin

Ertan Şahin

Faculty of Science, Department of Chemistry, Atatürk University, Erzurum, Turkey

Search for more papers by this author
Deniz Ekinci

Corresponding Author

Deniz Ekinci

Faculty of Agriculture, Department of Agricultural Biotechnology, Ondokuz Mayıs University, Samsun, Turkey

Faculty of Agriculture, Department of Agricultural Biotechnology, Ondokuz Mayıs University, 55139 Samsun, Turkey Fax: +90 362 4576034.Search for more papers by this author
First published: 07 May 2013
Citations: 44

Abstract

Here, we provide an alternative synthesis of the natural bromophenol 3,4-dibromo-5-(2,3-dibromo-4,5-dihydroxybenzyl)-6-(ethoxymethyl)benzene-1,2-diol (3) and the first synthesis of (4,5-dihydroxy-2-methylphenyl)(3,4-dihydroxyphenyl)methanone (18) and its brominated derivatives 1921. The compounds were characterized and tested against the two most studied members of the pH regulatory enzyme family, carbonic anhydrase (CA). The inhibitory potencies of the novel compounds and two natural bromophenols 2, 3 were analyzed at the human isoforms hCA I and hCA II as targets and the KI values were calculated. The KI values of the novel compounds were measured in the range of 13.7–32.7 µM for the hCA I isozyme and 0.65–1.26 µM for the hCA II isozyme. The structurally related compound 14 was also tested in order to understand the structure–activity relationship, and the clinically used sulfonamide acetazolamide (AZA) was tested for comparison reasons. All of the compounds exhibited competitive inhibition with 4-nitrophenylacetate as substrate. The compounds showed strong inhibitory activity against hCA I, being more effective as compared to the clinically used AZA (KI: 36.2 µM), but rather less activity against hCA II.

The full text of this article hosted at iucr.org is unavailable due to technical difficulties.